0
0
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial - The Lancet
10/20/23 at 10:43pm
Organization
The Lancet
Author
The Lancet
27 words
0
Comments
You are the first to view
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901796-8/fulltext
Create an account or login to join the discussion